Vimta Labs Ltd

Cyber security incident

• Detected cyber security incident affecting part of IT infrastructure; containment measures initiated and external experts engaged.
• Operations and customer delivery remained fully functional; root-cause assessment underway with no material impact identified.

Meeting Details

• Meeting 1: 3 July 2026, 03:30–04:30 PM, One-on-One, Virtual.
• Meeting 2: 3 July 2026, 04:30–05:30 PM, One-on-One, Virtual.
• Agenda: Understand company’s business operations.
• Organiser: Investment Analysts Meeting.
• Key participants: Sr Portfolio Manager, CIO, Sr. Professional.

Meeting Details

• Earnings/investor call for Q1 FY2026-27 held on 20 July 2026.
• Type: Earnings/investor call; Mode: audio recording.
• Event/Organizer: Vimta Labs earnings call.

Participants

• Key participant: Company Secretary and Compliance Officer.

Purpose

• Purpose: Earnings discussion and investor interaction for Q1 FY2026-27.

Additional Notes

• Audio recording available on the company website.

Financial highlights

• Total income for Q1 FY27: ₹1,129 Mn, up 13.7% YoY.
• EBITDA ₹411 Mn; EBITDA margin 36.4%.
• PBT ₹283 Mn.
• PAT ₹210 Mn; PAT margin 18.6%.
• Basic EPS ₹4.7.

Business developments

• Ukraine regulatory audit completed during the quarter.
• Biologics CRADS operations commenced.

Outlook

• Outlook: optimistic about industry prospects and expanding service portfolio.

Business Overview

• Contract research and testing provider across pharma, biologics, food, environment, and electronics; 10 labs nationwide.

Key Operational Highlights

• Q1 FY27 total income Rs 1,129 Mn; EBITDA Rs 411 Mn; PAT Rs 210 Mn.
• EBITDA margin 36.4%; PAT margin 18.6% for Q1 FY27.
• Capex cash outflow Rs 180 Mn in Q1 FY27.
• YoY growth: Total Income +11.1%; EBITDA +13.7%; PAT +16.0%.

Financial Performance

• FY26 total revenue ₹4,163 Mn; EBITDA ₹1,489 Mn; PAT ₹775 Mn.
• EBITDA margin rose from 29% (FY22) to 36% (FY25) and PAT margin to ~19%.
• Debt-to-Equity declined to 0.01 in FY26; ROE 17%; ROCE 21%.

Capital Structure & Liquidity

• Debt-to-Equity at FY26: 0.01 indicating low leverage.

Strategic Priorities & Outlook

• Growth drivers include capacity expansions, service innovations, and market penetration.
• Operational focus on governance, risk management, talent, and cutting-edge technology.
• Way Forward emphasizes customer partnerships and robust quality/compliance culture.

Governance & Leadership

• MD: Harita Vasireddi; Executive Chairman: S P Vasireddi; promoter director Harriman Vungal.
• CFO: Siva Kambhampati; senior CRO industry experience.

Financial results approved

• Unaudited quarterly results for quarter ended 30 June 2026 approved by the Board; Audit Committee recommended.

Auditor’s review

• Independent auditor’s review report issued with unmodified opinion; no material misstatement detected.

Segment and SCA revenue

• Single reportable segment: Contract Research and Testing Services.
• FSSAI PPP/SCA with NFL Mumbai; lab setup revenue recognized.
• Lab setup revenue under SCA totaled 0.45 million in Q1 2026.
• Revenue under SCA for year ended 31 Mar 2026: 1.20 million.

Key financial items

• Past service cost due to Labour Codes: 16.16 million, classified as exceptional item.
• Employee benefits expense includes 8.46 million from ESOP vesting.

ESOP grant and governance

• Grant of 40,500 options under ESOP 2021 approved by Nomination and Remuneration Committee.
• Board approval of ESOP grant noted; effective 20 July 2026.
• No subsidiary/associate/joint venture in the quarter.

Regulatory and auditor remarks

• Auditor notes no Emphasis of Matter; no regulatory irregularities disclosed.

Meeting Details

• Date and time: Monday, 20 July 2026 at 4:00 PM IST.
• Type and mode: Group virtual conference call.
• Event: Q1FY27 Results Conference Call; Organiser: Systematix Institutional Equities.
• Participants: MD, Executive Director, CFO, Company Secretary.
• Purpose: Earnings results discussion for Q1FY27.

Meeting Details

• Board meeting scheduled for Monday, 20 July 2026; time and venue not disclosed.

Key Agenda Items

• Approve unaudited quarterly results for quarter ended 30 June 2026 (standalone/consolidated not specified).

Other Notes

• Trading window closed from 01 July 2026 until 48 hours after results announcement.

Dematerialisation request status

• No dematerialisation requests were received during the reporting period.